Overview
Vimentin is an intermediate filament protein expressed mainly in cells of mesenchymal origin. It is also known as an anti-vimentin antibody when referred to in immunological testing. This gene is located on chromosome 10 and plays an important role in maintaining cellular structure and integrity. It is widely used as a marker of epithelial–mesenchymal transition, a process associated with tumor progression and metastasis.
It is considered a relatively non-specific marker. Most carcinomas and epithelial tumors are usually negative, while mesenchymal tumors show strong positivity. Because of this, It is commonly used in combination with other markers for diagnostic interpretation rather than as a standalone test
Symptoms
Vimentin itself does not cause symptoms. Clinical features depend on the underlying condition where vimentin expression is altered or detected. In malignancies, symptoms vary according to tumor type, site, and stage.
In inflammatory and systemic conditions, elevated serum vimentin levels may be associated with endothelial injury. In pediatric severe sepsis, high serum vimentin levels are linked with poor prognosis and increased risk of mortality.
In oral cancers, higher serum vimentin levels are associated with disease progression, moving from normal tissue to benign conditions and then to malignant states. Symptoms in such cases include non-healing ulcers, pain, swelling, and difficulty in chewing or swallowing.
Causes
Its expression increases due to activation of epithelial–mesenchymal transition. During this process, epithelial cells lose polarity and adhesion and acquire mesenchymal features that enhance migration and invasiveness.
In cancer, overexpression of vimentin reflects aggressive tumor behavior and metastatic potential. It is commonly seen in mesenchymal tumors, sarcomatoid and rhabdoid renal cell carcinoma, meningioma, ependymoma, adrenal cortical carcinoma, thyroid carcinomas, and certain gynecological and pancreatic tumors.
Elevated serum vimentin levels may occur due to endothelial injury, systemic inflammation, or severe infection. In pediatric severe sepsis, increased levels indicate vascular damage and worse outcomes.
Risk Factors
Risk factors related to abnormal vimentin expression are mainly linked to malignancy, chronic inflammation, and severe systemic illness. Tumors undergoing epithelial–mesenchymal transition show increased vimentin expression.
Patients with advanced or aggressive cancers are more likely to show vimentin positivity, especially in mesenchymal and sarcomatoid tumors. Chronic inflammatory states and severe infections increase the likelihood of elevated serum vimentin.
In oral premalignant conditions such as oral submucous fibrosis, rising of these levels indicates increased risk of malignant transformation. Progression from benign to malignant disease increases this expression.
Prevention
There is no specific prevention expression, as it reflects underlying disease processes rather than a primary disorder. Prevention focuses on early detection and management of associated conditions.
Regular screening and early diagnosis of cancers reduce progression to aggressive stages where vimentin expression is high. Monitoring circulating tumor cells using liquid biopsy helps track disease progression and metastasis.
Control of systemic infections, prompt treatment of sepsis, and early intensive care management reduce endothelial injury and the associated rise in serum vimentin. Interpretation results should always be combined with clinical findings and other diagnostic markers to guide appropriate management.
